Brain-CNS expansion Dyne Therapeutics demonstrates CNS-targeting capabilities via the FORCE platform and plans to cross the blood-brain barrier to knock down MAPT RNA in the CNS, indicating potential for CNS-focused collaborations and joint development opportunities alongside neuromuscular programs.

Rare disease focus With programs in Duchenne muscular dystrophy, myotonic dystrophy type 1, and preclinical work in FSHD and Pompe disease, there are multiple high-need genetic neuromuscular targets ripe for strategic partnerships, co-development, or licensing discussions.

Clinical-stage momentum As a clinical-stage company with ongoing preclinical data presentations and participation in major conferences (ASGCT, JPM Healthcare), there are opportunities to align with investors, collaborators, and service providers around upcoming data milestones.

Strategic leadership Recent board appointments and senior hires in corporate development and research translation signal a push toward strategic partnerships, licensing deals, and expanded business development capabilities to accelerate product progression.

Data-enabled ops Dyne’s tech stack includes cloud, analytics, and data platforms (Azure, MySQL, IQVIA, analytics tools), suggesting a readiness for deep, data-driven collaborations, real-world evidence generation, and CRO/clinical data partnerships.